Tumor VEGF-C expression (compared with no expression) was associated with significantly shorter median PFS and above-median OS in a subgroup of sunitinib monotherapy trials of patients with GC, but tumor control rates did not differ (153). This evidence concerns the gene VEGFC and gastric cancer.